



BioMarker
STRATEGIES

News Release

Contact:

Scott Allocco, President

410-522-1008

sallocco@biomarkerstrategies.com

FOR IMMEDIATE RELEASE

October 7, 2009 at 8 am

BioMarker Strategies Awarded Fast-Track SBIR Contract from National Cancer Institute to Develop SnapPath™ System

Baltimore, Md—October 7, 2009—BioMarker Strategies, LLC announced today that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) contract from the National Cancer Institute to develop the SnapPath™ live-tumor-cell testing system. BioMarker Strategies is developing the SnapPath™ system to enable oncologists to determine the most effective drug treatment for their cancer patients. Under this contract, the company will receive an initial award of \$254,000 and be eligible to receive an additional \$2 million when the first phase of work is completed—for a total potential contract amount of \$2.3 million.

“We are gratified by this award from the NCI to support the development of our SnapPath™ technology and plan to use these funds to expedite production of a prototype of our live-tumor-cell testing system,” said Kären Olson, CEO of BioMarker Strategies.

BioMarker Strategies was awarded this funding under NCI contract opportunity #257, *Biopsy Instruments and Devices that Preserve the Molecular Profiles in Tumors*, designed to identify “innovative approaches for tumor biopsy that preserve the molecular profile (that) will create an entirely new diagnostic area and market in molecular therapeutics, which will not only facilitate pharmacodynamic assessment of targeted therapeutics but also enable individualized molecular therapy of solid tumors based on accurate information about signal transduction pathways, molecular drug targets and biomarkers.” (see NCI contract announcement #257/PHS-01-2009).

In addition to SnapPath™, BioMarker Strategies is developing a series of functional, pathway-based, ex vivo biomarker tests to help guide the use of targeted cancer therapeutics. The company recently raised approximately \$1.7 million from private investors, including the Abell Foundation, to support the development of the SnapPath™ system. BioMarker’s facilities are located at the Johns Hopkins Science + Technology Park in East Baltimore. For more information about BioMarker Strategies, please go to www.biomarkerstrategies.com.

#

NEWS RELEASE

Some of the information in this release contains our projections or other forward-looking statements regarding future events. We wish to caution you that these statements are only predictions and actual events or results may differ materially. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. Forward-looking statements included herein are made as of the date hereof, and we undertake no obligation to update publicly such statements to reflect subsequent events or circumstances. Actual results could differ materially from anticipated results.

#